<DOC>
	<DOCNO>NCT01877629</DOCNO>
	<brief_summary>To explore pharmacokinetics ( PK ) single dose two different formulation ACT-129968 , i.e. , tablet versus capsule evaluate safety tolerability single dose two different formulation ACT-129968 , i.e. , tablet versus capsule .</brief_summary>
	<brief_title>Study Healthy Subjects Assess Pharmacokinetics , Safety , Tolerability Two Formulations ACT-129968</brief_title>
	<detailed_description>A total 10 female 10 male healthy subject enrol attend two treatment period , separate 7-9 day washout . Over two period , two formulation ACT-129968 ( Treatment A : two capsule , 250 mg ; Treatment B : one tablet , 500 mg ) administer sequence A/B B/A 10 subject ( 5 female 5 male ) per sequence determine randomization .</detailed_description>
	<criteria>Signed informed consent local language prior studymandated procedure . Women must negative serum pregnancy test screen negative urine pregnancy test predose Day1 treatment period . Women childbearing potential must consistently correctly use ( screening , entire study , least 28 day last study drug intake ) reliable method contraception failure rate &lt; 1 % per year , sexually inactive , vasectomized partner . Women childbearing potential define postmenopausal ( i.e. , spontaneous amenorrhea least 1 year without alternative medical cause ) surgically naturally sterile . No clinically significant finding physical examination screening . Body mass index ( BMI ) 18.0 28.0 kg/m^2 ( inclusive ) screening . Systolic blood pressure ( SBP ) 100145 mmHg , diastolic blood pressure ( DBP ) 5090 mmHg , pulse rate ( PR ) 4590 bpm ( inclusive ) , measure dominant arm ( dominant arm = write arm ) 5 minute supine position screening . 12lead electrocardiogram ( ECG ) without clinically relevant abnormality , measure 5 minute supine position screening . Hematology , clinical chemistry , urinalysis test result deviate normal range clinically relevant extent screening . Negative result urine drug screen breath alcohol test screen admission unit ( Day1 ) Period 1 Period 2 . Ability communicate well investigator , local language , understand comply requirement study . Pregnant lactate woman . Known allergic reaction hypersensitivity excipient drug formulation ( ) . History clinical evidence disease and/or existence surgical medical condition might interfere absorption , distribution , metabolism , excretion study drug ( appendectomy herniotomy allow , cholecystectomy allow ) . Previous history fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction . History clinical evidence allergic rhinitis asthma . Veins unsuitable intravenous puncture either arm ( e.g. , vein difficult locate , access , puncture , vein tendency rupture puncture ) . Previous exposure study medication . Treatment another investigational drug within 3 month prior screen participation four investigational drug study within 1 year prior screen . History clinical evidence alcoholism drug abuse within 3year period prior screen . Excessive caffeine consumption , define 800 mg per day screening . Alcohol consumption &gt; 21 units/week &gt; 3 units/day . Smoking within 3 month prior screen . Previous treatment prescribe overthecounter medication ( include herbal medicine St John 's Wort ) within 2 week prior first study drug administration . Loss 250 mL blood within 3 month prior screen . Positive result hepatitis serology ( Hepatitis B surface antigen antihepatitis C virus ) , except vaccinated subject subject past resolve hepatitis ( define positive finding antibody negative finding antigen ) , screen . Positive result human immunodeficiency virus serology screen . Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol . Legal incapacity limit legal capacity screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>ACT-129968</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>